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Abstract: A novel mixed platinum(II) complex with general for-
mula [Pt(PPh3)2(L1-O,S)]PF6 has been synthetized and character-
ized by elemental analysis, molar conductivity, and by IR and
NMR (1H, 13C and 31P) spectroscopic methods. The crystal struc-
ture has been determined by single-crystal X-ray crystallogra-
phy. The molecule presents an almost ideal square-planar
geometry, and the crystal is stabilized by weak C–H···O and
C–H···F hydrogen bonds, and C–H···π stacking interactions. The
steric congestion of ligands is described by “exact” cone and
1. Introduction
N-alkyl/aryl- (H2L) and N,N-di(alkyl/aryl)-N′-benzoylthiourea (HL)
have attracted interest in view of their selective co-ordination
towards transition metals, and particularly the platinum group
metals, leading to a wide range of bioactivity,[1–3] including
cytotoxic activity against cancer, including leukemia and solid
tumors.[4–5] These properties have also been observed in metal
complexes with acylthiourea derivatives.[6–9] Furthermore, the
acylthioureas are characterized for altering electronic and steric
effects in its metal complexes, which have made possible the
design of effective industrial catalysts.[10–12]
On the other hand, it is well known that the phosphines
have many applications in organometallic chemistry, specifically
as ligands in homogeneous catalysts,[13] and it has curiously
been reported that RuII, RuIII, CoIII and CuI complexes containing
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solid cone angles, and the percentage of metal surface shielded
by the ligands. The results are compared to closely related palla-
dium complexes. The X-ray structure revealed the proximity of
the ortho phenyl proton of one PPh3 ligand to platinum(II)
showing rare intramolecular C–H···Pt anagostic binding inter-
action. The title complex was determined to be active against
tumor cells, and it also showed a moderate inhibitory action
against mycobacterium tuberculosis.
N-di(alkyl/aryl)thiourea together with triphenylphosphine
present catalytic activity for the oxidation of alcohols.[12] In the
triphenylphosphine-containing complexes, the conformation of
the phenyl rings often contributes to the bulkiness of the com-
plex, which is interesting because the bulkiest part of the mol-
ecule generally determines its shape and reactivity.[14]
There are in the literature suggestion that the addition of
the triphenylphosphine the hydrophobicity of the complexes
increase, resulting in more cytotoxic activities, probably due the
increasing of drug uptake.[15–16] Indeed, ruthenium(II) arene
complexes containing the triphenylphosphine as ligand dis-
played IC50 values lower than those found for cisplatin toward
some cancer cells.[16–17]
The influence of steric effects of a ligand on the structures
and reaction rates of organometallic and coordination com-
pounds has been discussed in the literature using Tolman′s
cone angle (θ).[18] Taking into account the inaccuracy of several
empirical parameters that were assumed by Tolman, X-ray crys-
tal structure data have been used as a basis for estimating
ligand cone angles of phosphine ligands from the atomic coor-
dinates observed in the crystal structures of transition metal
phosphine compounds.[19]
Recently, the “exact” cone angle (θ°) has been presented as
a new ligand steric descriptor based on the idea of covering
the ligand in the most acute possible cone, being also useful
for determining the cone angle of any ligand, particularly for
environments with free rotation.[20] An interesting cone angle
history can be found in literature, which offers a detailed expla-
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nation on the need to develop a method for computing the
cone angle in any situation.[21]
Other descriptors used for quantifying steric demand are the
solid cone angle (Θ) and solid angle (Ω),[19b] the former derived
from the area filled by the ligands on the surface of a sphere
centered at the metal atom, and the latest associated to the
shadow cone of a ligand supposedly illuminated from the metal
center. The “exact” solid cone angle (Θ°) of ligand[21–22] cannot
be modeled using the cone angle model, and it is especially
useful in the case of multidentate ligands rotationally hindered.
The solid angle (Ω) can be calculated to quantify the total steric
shielding through the so-called G-parameters.[23] Thus, the G(L)
and G(M) parameters describe the ligand and metal surface
shielding, respectively, as a percentage of the maximum solid
angle (4π steradians), whereas G(complex) parameter gives the
G value for the entire complex, all ligands treated as one.
In this work we report the synthesis, spectroscopic proper-
ties, crystal structure and biological activity of cis-[Pt(PPh3)2-
(L1-O,S)]PF6 complex ((L1-O,S = N,N-morpholine-N′-benzoylthio-
urea), focusing our interest in the coordination geometry, the
steric demand of both the ligands, and antitumor and anti-
bacterial activity. It is reported that only the crystal structures
of the mononuclear complexes TcIII, ReIII,[24] and PdII,[25] as well
as the RhI dinuclear complex[26] containing triphenylphosphine
and benzoylthiourea respectively, so this work can contribute
to preclinical studies and the development of new reagents and
catalysts to be used in organic synthesis.
2. Results and Discussion
2.1. IR Spectra
Infrared spectra suggest the formation of the complex by de-
protonation of L1-O,S free ligand during its coordination to
platinum ion. Thus, the typical NH stretching that appears as a
wide and strong absorption at 3279 cm–1 in the free ligand,
disappears after its coordination to the metal (Figure S1). By
the other hand, the band ν(CN) at 1481 cm–1 in the complex is
absent in the free ligand, suggesting the formation of a hetero-
cyclic ring according to Scheme 1. In addition, the band at
1517 cm–1 is assigned to C=O group in the complex, and the
vibration frequency is decreased when compared to the corre-
sponding band at about 1661 cm–1 for the free ligand, in agree-
ment with the literature.[27] The absorption at 878 cm–1 in the
free ligand is attributed to the ν(C–S) stretching, shifted to the
769 cm–1 in the complex. The absorption at 471 cm–1 is as-
signed to the Pt–O vibration mode and the assignment of the
Pt–S stretching at about 360 cm–1 is in accordance with the
literature.[28–31] These results suggest that L1 ligand is attached
Scheme 1. Synthesis of cis-[Pt(PPh3)2(L1-O,S)]PF6 (L1-O,S = N,N-morpholine-
N′-benzoylthiourea).
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to the metal through the oxygen and sulfur atoms in a chelat-
ing form. By the other hand. The IR spectrum shows signals
associated with the presence of PPh3 ligand and the PF6- anion,
thus, signals at 3057, ν(C–H) (PPh3); 842, ν(P–F); 692, νP-Ph
(Ph3–P–Ph3); 550, ν(Pt–P) cm–1 as reported in previous work,[32]
suggesting direct coordination of the phosphorus atom to the
platinum ion, in agreement with the results of crystal structure
determination (Figure S2).
2.2. 1H NMR, 13C NMR and 31P NMR Spectra
The 1H NMR spectrum of the L1-O,S free ligand basically shows
three sets of well-separated signals corresponding to the benz-
ene substituents, morpholine ring and the NH proton (Figure
S3). The latter appears as a singlet at 8.60 ppm and disappears
after coordination to the metal.[33–34] The methylene protons in
the morpholine ring appear as two broad triplets at 4.22 and
3.65 ppm, and a multiplet at 3.83 ppm that integrates four pro-
tons, because they are attached to the nitrogen atom. All the
protons present in the complex appear at higher chemical shifts
than in the free ligand. The aromatic protons are visible as a
complex pattern in the region 8.13–7.00 ppm as in related com-
pounds.[28] The signals corresponding to the methylene protons
in morpholine ring (Figure S4) are observed in form of triplets
ranging from 4.22 to 3.65 ppm. 13C NMR spectrum of the L1
free ligand shows signals at 179.25 and 163.30 ppm which are
ascribed to the carbon atoms of C=S and C=O groups, respec-
tively (Figure S6). However, the former signal is shifted to higher
field by 9.64 ppm, and the latter signal to lower field by
4.49 ppm in the complex (see Figure S7).
31P {1H} NMR spectrum of complex indicates that there are
two coordinated triphenylphosphine ligands in cis position. The
precursor [PtCl2(PPh3)2] in CH2Cl2 solution shows a singlet peak
for phosphorus atoms at 13.72 ppm, whereas the complex
shows two doublets at about 20.55 and 9.34 ppm revealing
the existence of two magnetically different phosphorus atoms
bonded to platinum(II) ion. A multiple signal of the PF6– anion
appears in the region 138–158 ppm (Figures S8 and S9) as in
similar complexes previously reported.[35] The molar conductiv-
ity shows that the complex is a cationic species.[36]
2.3. X-ray Structure
The ORTEP diagram of title complex is shown in Figure 1 with
atom numbering scheme Selected bond lengths, bond angles
and torsion angles are summarized in Table S1 (Supporting In-
formation). The platinum(II) ion is coordinated by two phos-
phorus atoms of two bulky triphenylphosphine ligands, and the
oxygen and sulfur atoms of one bidentate L1 ligand forming a
four-coordinate cis-planar geometry as occurs in the structural
chemistry of bis-chelates benzoylthioureas with d8 or d9 ions.[37]
A PF6– group acts as outer-sphere anion of the complex. The τ4
index has been proposed to describe the geometry of four-
coordinate complexes, with values falling between 1.00 for a
perfect tetrahedral geometry and zero for an ideal square-
planar geometry.[38] The τ4 index calculated for title complex is
equal to 0.06 indicating an almost perfect square planar envi-
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ronment around the PtII ion. The Pt–O [2.061(4) Å], Pt–S
[2.308(2) Å] and Pt–P [average 2.277(1) Å] bond lengths are
comparable to those observed in similar complexes.[39,40] The
lengths of C–O, C–S and C–N bonds in the chelate ring are
between characteristic single and double bond lengths as result
of the existence of electronic delocalization.
Figure 1. ORTEP diagram of the title complex with heteroatom numbering
scheme and ellipsoids at 30 % probability level; H-atoms are omitted for clar-
ity.
A clearly puckered system is observed for the six-membered
morpholine ring. The q(3) puckering amplitude value
(–0.5524 Å) is very longer than the corresponding q(2) ampli-
tude value (0.0580 Å), which is very close to zero. The q(3) value
is also very similar to the total puckering amplitude QT =
0.555 Å, which lies slightly under the QT value of 0.63Å for ideal
cyclohexane chair.[41] These results indicate that the morpholine
ring adopts a slightly distorted chair conformation. The crystal
packing (Figure 2) reveals that the complex is stabilized by
weak C–H···O hydrogen bonds forming dimers R22(8), weak
C–H···F hydrogen bonds involving four fluorine atoms of the
PF6– anion, and a significant intermolecular C–H···π interaction
(H125···Cg4 = 2.66 Å, Cg4 = centroid of C111–C116 ring)[42] in-
volving phenyl rings. Geometry of intermolecular interactions is
shown in Table S2 (Supporting Information).
Table 1. Exact cone θ° angle of M–PPh3 (M = metal) fragment, exact solid cone Θ° angle of M–Th fragment, and G-parameters[a] for 1 and palladium related
complexes.
Complex Formula[b] θ0 [deg] Θ°[deg] G-parameters [%]
M–PPh3 M–Th Complex Metal
1 [Pt(PPh3)2(L1-O,S)]·PF6 171.9 139.6 81.1 68.2
159.2 – – –
YIXRUU [PdCl(PPh3)(L2-O,S)] 158.5 141.4 70.7 65.2
YIXROO [Pd(PPh3)2(L3-O,S)]·PF6 164.7 144.1 83.0 67.6
169.5 – – –
YIXSOP [Pd(PPh3)2(L4-O,S)]·PF6 163.4 146.2 83.3 67.2
169.3 – – –
YIXREE [Pd(PPh3)2(L5-O,S)]·PF6 178.3 141.4 81.3 68.0
154.9 – – –
YIXRII [Pd(PPh3)2(L6-O,S)] 169.6 143.5 82.9 67.4
165.1 – – –
[a] G(complex) = The G value for the complex, all ligands treated as one; G(metal) = percentage of metal surface shielded by the ligated atoms only. [b] L1-
O,S = N,N-morpholine-N′-benzoylthiourea; L2-O,S = N,N-dimethyl-N′-benzoylthiourea; L3-O,S = N,N-diphenyl-N′-benzoylthiourea; L4-O,S = N,N-dibenzyl-N′-
benzoylthiourea; L5-O,S = N,N-diethyl-N′-furoylthiourea; HL6 = N,N-diphenyl-N′-furoylthiourea.
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Figure 2. View of crystal packing for title complex. Hydrogen bonds and
C–H···π contacts are shown as dashed lines. Symmetry codes: (i) –x, 1 – y,
1 – z; (ii) 1 – x, 1 – y, –z.
2.3.1. Steric Description of the Ligands
In order to measure the steric demand of ligands, the “exact”
cone (θ°) angles of the two M – PPh3 (M = metal) fragments for
title complex (hereafter 1) were calculated and compared with
five closely related PdII complexes editorial query: the CSD Ref-
code are given in Table 1[25]. The results listed in Table 1 show
longer exact cone angle values than that the idealized Tolman
standard value of 148°[18] for all structures in agreement to the
literature,[20] with similar mean absolute deviations of 17.6 and
17.9°, respectively. The higher cone angle value of one PPh3
ligand for 1 (θ° = 171.9°) is slightly longer than the correspond-
ing average value of 169.0° for Pd complexes, supporting the
fact that in general as the actual M–P distance increases (from
2.241/2.314 Å for Pt to average 2.258/2.346 Å for Pd), the cone
angle should decrease.[20] Unlike YIXRUU, the remaining com-
plexes appear bonded by two PPh3 ligands (Table 1) showing
remarkable internal mismatches of 12.7° and (4–9°) in their cone
angles for Pt and Pd complexes, respectively. The observed dif-
ferences reveal the significant effect of the chemical environ-
ment on the steric bulk of a ligand.
Full Paper
Table 2. IC50 values of complex 1, precursor complex, ethambutol, cisplatin and ligand L1-O,S in cell lines (L929, MDA-MB 231, and DU-145) after 48 hours of
incubation, selective index (SI) and MIC values of anti-mycobacterial activity.
IC50 (μmol L–1) MIC
Compound DU-145 MDA-MB-231 L929 SI[a] SI[b] μg/mL μmol/L
1 3.09 ± 1.1 6.92 ± 0.60 > 100 > 32.36 > 14.45 > 25 > 22.40
[PtCl2(PPh3)2] > 100 > 100 16.53 ± 2.3 – – > 25 > 47.32
Ethambutol – – – – – 1.02 5.62
Cisplatin 2.00 ± 0.20 2.43 ± 0.20 > 100 > 8.26 > 6.80 – –
L1 > 100 > 100 > 100 – – > 25 > 25
[a] IC50L929/IC50DU-145. [b] IC50L929/IC50 MDA-MB-231; L1-O,S = N,N-morpholine-N′-benzoylthiourea.
To avoid the complications with cone angles for estimating
the steric demand of multidentate ligands, and the steric
crowding about the metal center when several ligands are
present,[22] instead of θ° we have calculated the “exact” solid
cone angles Θ° of the bidentate morpholine-thiourea ligand for
1 and the five related palladium complexes (Table 1). The Θ°
values vary from 139.6° for 1 to 146.2° for YIXSOP correlating
well with the bulk of substituents at the thiourea backbone, as
expected. That way, bulkier substituents, higher the solid cone
angle. In the series of palladium complexes, the lower Θ° value
of 141.4° corresponds to YIXRUU and YIXREE with small dialkyl-
thiourea ligands, in comparison to the other three complexes
with bulkier diaryl-thiourea ligands. The big diphenyl group en-
larges Θ° by 2.1° for YIXRII complex, and a little longer (2.7°) for
YIXROO due to the increased size of the benzoyl ring related to
the furoyl ring in the former complex. The presence of the bulk-
iest dibenzyl group is compatible with the maximum enlarge-
ment (4.8°) of Θ° for YIXSOP.
In order to evaluate the probability of an incoming reagent
not accessing the metal center, the percentages of metal coor-
dination sphere shielded by each ligand [G(L)], the G value for
the complex with all ligands treated as one cumulative ligand
[G(complex)], and percentage of metal surface shielded only by
the ligated atoms [G(M)] were computed from ligand solid an-
gles Ω (Table S3, Supporting Information), using zero energy
point radii (rZ) instead of the van der Waals radii.[23]
A Solid G view for complex 1 is shown in Figure 3 highlight-
ing the areas of the ligands (2PPh3 and L1) projection shadow
onto a sphere of an arbitrary radius. The percentage of the
sphere shielded by the thiourea L1 ligand (32.8 %) is longer
Figure 3. View of projection of L1 (blue) and PPh3 (green and gray) ligands in
complex 1 onto a sphere of an arbitrary radius of 10 Å. The Pt atom is shown
as a large grey sphere of an arbitrary radius for easy visualization.
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than those by the PPh3 ligands (average 27.1 %), and hence the
remaining open area (white) of the sphere where an incoming
reagent could bind represents only 13.1 %. The G(complex)
value indicate that all the ligands shield 81.1 % of the plati-
num's coordination sphere, whereas the G(Pt) value of 68.2 %
denote that there is only a 31.8 % chance that an incoming
reagent reaches the metal center. The G(Pd) values are slightly
shorter (67.2–68.0 %) for the four palladium complexes bonded
by two PPh3 ligands (Table 1), and even shorter (65.2 %) for
the chloro complex (YIXRUU) as result of its decreased steric
crowding about the Pd atom.
2.3.2. Anagostic Interactions
The packing effects together with the steric and electronic hin-
drance of both bulky PPh3 ligand and diamagnetic d8 square-
planar PtII allow the aromatic ortho-proton H122 of a PPh3
group to be nearly close to one of the vacant positions around
the platinum atom, leading to a rare intramolecular anagostic
interaction with Pt···H122= 2.851(1) Å and C122–H···Pt = 123°.
Anagostic C–H···M interactions are characterized by relatively
long M···H distances (2.3 to 2.9 Å) and large angles (110 to
170°), in comparison to agostic interactions which are charac-
terized by relatively short M–H distances (1.8 to 2.3 Å) and
C–H···M angles ranging from 90 to 140°.[43–45] Anagostic inter-
actions are interesting due to possible influences on the mecha-
nism of C–H activation.[46–48]
Furthermore, the effect of the intramolecular Pt···H–C inter-
action on the donor phosphine ligand has been analyzed by
the closely inspection of the infrared spectra in the C–H stretch-
ing vibration. This is a crowded region because of the many
C–H bonds present in the complex, but a very strong band is
observed at 3057 cm–1, which can be assigned to the C–H
stretching mode in the phosphine group.[49,50] It is accepted
that anagostic interactions is mostly electrostatic in character,
in line with the strong C–H absorption observed in the infrared
spectrum. Also, the comparison of the proton signals in the 1H
NMR spectra of the ligand and the complex shows that signals
due to the benzene ring in the phosphine complex appear at
higher fields.
2.4. Biological Activity
The effect of the PPh3 group in the antitumor activity of RuII
complexes has been studied by Sáez et al. and a noticeable
increment of the antitumor activity and cytotoxicity of the com-
plexes was found due to the presence of the PPh3 ligand.[16]
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Similarly, the high cytotoxic activity in vitro of RuII complexes
containing cymene and phosphine ligands reported by was at-
tributed to RuII species still bearing the phosphorus ligand
bounded to the metal center.[17]
The free ligand, the title complex 1 and precursor
[PtCl2(PPh3)2] were tested against the tumor cells (L929, MDA-
MB 231 and DU-145) and compared with the cytotoxicity of
cisplatin as well as evaluated under the same experimental
conditions as it appears in Table 2. The IC50 value of
16.53 ± 2.38 μmol L–1 was calculated from the dose-survival
curve generated by the MTT assay obtained after drug treat-
ment. As can be seen, the value of IC50 (> 100 μg/mL) for the
complex is very high for L929, indicative of selectivity toward
tumor cell. The free ligand and the complex were also tested in
strains of mycobacterium tuberculosis (H37Rv ATCC 27294) using
the MABA methodology. The MIC values >25, and 1.02 μg/mL
for the free ligand, complex and ethambutol, respectively, are
shown in Table 2.
As can be seen from Table 2, the complex 1 in general is
more cytotoxic than the precursor, [PtCl2(PPh3)2]. This is proba-
bly due to the fact the compound is anionic, and more soluble
in the biological medium than the [PtCl2(PPh3)2] complex.
Worth it to mention that the [PtCl2(PPh3)2] complex is stable in
DMSO/H2O (9:1) solution for at least 96 h, as showed by 31P{1H}
NMR (Figure S10).
The selective indexes of complex (1) for the DU-145 and
MDA-MB-231 are much higher than those found the PdII com-
plexes of N,N-disubstituted-N′-acylthioureas.[25]
According to the data from Table 2, the complex showed a
moderate inhibitory action against mycobacterium tuberculosis
(H37Rv ATCC 27294) when compared to the reference drug
(ethambutol). Also, the observed MIC values suggest that the
complex is active against the tumor cells MDA-MB 231
(6.92 ± 0.60) and DU-145 (3.09 ± 1.1), although lower than other
platinum(II) and palladium(II) complexes previously obtained by
us.[25,50,51]
3. Conclusions
A new ligand mixed PtII complex with triphenylphosphine and
benzoylthiourea, cis-[Pt(PPh3)2 L1-O,S]PF6 (1), has been synthe-
tized, fully characterized, and its structure determined by X-ray
diffraction showing almost perfect square-planar coordination
geometry. A rare intramolecular anagostic C–H···Pt interaction
is detected, and the crystal packing is stabilized by weak
hydrogen bonds and C–H···π interactions. Calculations of steric
descriptors for 1 and related PdII compounds revealed sterically
congested complexes. The complex presents cytotoxic and anti-
mycobacterial activity. Information obtained from this work
may be useful to initiate pre-clinical studies of title complex,
and for the design of new catalysts.
4. Experimental Section
4.1. Materials and measurements
The precursor [PtCl2(PPh3)2] was obtained from Sigma. All reagents
were purchased with reagent grade and used without further purifi-
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cation. Solvents were dried and used freshly distilled, unless other-
wise specifically indicated. Thin layer chromatography (TLC) was
performed on 0.25 mm silica gel pre-coated plastic sheets
(40/80mm) (Polygram-SIL G/UV254, Macherey & Nagel, Düren, Ger-
many) using benzene (caution)/methanol (9:1) as eluent. The deter-
mination of C/H/N/S was done using a Fisons – EA-1108 CHNS Ele-
ment Analyzer. The IR spectra were recorded on a FT-IR Bomem-
Michelson 102 spectrometer in the 4000–200 cm–1 region using KBr
pellets. The molar conductivity Λm was obtained on a Meter Lab
CDM2300 instrument using 1.0 mM solution of complex in dichloro-
methane. 1H, 31P{1H} and 13C{1H} NMR spectra were recorded on a
Bruker DRX 400 MHz, internally referenced to TMS, chemical shift
(δ), multiplicity (m), spin–spin coupling constant (J), integral (I).
CDCl3 was used as solvent. The displacement 31P {1H} is reported in
relation to H3PO4 (85 %). NMR experiment with Single Hetero-
nuclear 2D Quantum Coherence (HSQC) was performed in order to
unambiguously assign the C=O and C=S signals of the complex.
4.2. Synthesis of N,N-morpholine-N′-benzoylthiourea (L1)
Intermediate compound N,N-morpholine-N′-benzoylthiourea was
synthesized as described previously, and identity of the product
was confirmed by comparing their 1H and 13C{1H} NMR data with
those reported in literature.[52] Yield: 0.213 g (85 %), Anal. Calcd. for:
[C12H14N2O2S]: C, 57.58; H, 5.64; N, 11.19; S, 12.81 %; found C, 57.00;
H, 5.50; N, 10.90; S, 12.00 %. IR (KBr; ν/cm–1): 3279 (N–H), 2980
(C–H), 1661 (C=O), 1603 (C=C), 1520 (band I N–C=S), 1475(C–O–C)
1267 (band II N–C=S), 1114 (band III N–C=S), 932 (band IV N–C=S).
1H NMR (CDCl3, δ, ppm): 8.60 (1H, s, NH1, exchange with D2O), 7.84–
7.46 (m, 5H, Ph), 4.22 (t, 2H, CH2), 3.83 (m, 4H, CH2), 3.65 (m, 2H,
CH2) 13C NMR (CDCl3, δ, ppm): 179.25 (C=S), 163.30 (C=O), 133.20–
127.83(Ph), 66.22 (CH2-O), 52.55, 51.60 (CH2-N).
4.3. Synthesis of cis-[Pt(PPh3)2(L1-O,S)]PF6 {cis-bis(triphenyl-
phosphine)(N,N-morpholine-N′-benzoylthioureato-k2O,S)plati-
num(II) hexafluorophosphate}
A solution of [PtCl2(PPh3)2] (1.580 g, 2 mmol) in 5 mL of methanol
was added dropwise to a solution of L1-O,S (0.50 g, 2 mmol) dis-
solved in 30 mL of the same solvent, and KPF6 (0.368 g, 2 mmol)
(Scheme 1). The mixture was heated under magnetic stirring at
80 °C for 2 h, and later left overnight into the refrigerator. The white
solids obtained were filtered off and washed successively with hot
water and hot hexane (3 × 20 mL). Yield: 1.77 g (80 %). Anal. Calcd.
for C48H43F6N2O2P3PtS: C, 51.76; H, 3.89; N, 2.51; S, 2.88 %; found C,
5 2 . 4 8 ; H , 4 . 3 0 ; N , 3 . 0 5 ; S , 2 . 7 0 % ; m . p. 2 4 9 – 2 5 1 ° C ; Λ m =
47.6 Ω–1 cm2 mol–1. IR (KBr; ν/cm–1): 3057, ν(CHPPh3); 1585 ν(C=N);
1497, ν(C=O); 842, ν(P–F); 743, ν(C=S); 692, ν(Ph3–P–Ph3); 550, ν(Pt–
P). 1H NMR (400MHz, CDCl3): δ (ppm) = 8.12–7.00 (30 H-atoms of
PPh3, 5 H-atoms of Ph), 4.19 (t, 2H, CH2), 3.78 (t, 2H, CH2), 3.68 (bs,
4H, CH2); 13C{1H} NMR (100 MHz, CDCl3): δ (ppm) = 169.61 (C=S),
167.79 (C=O), 134.55, 134.44, (d, Cmeta-PPh3, 3JC–P10.63, 10.48 Hz),
132.31, 131.85 (Cpara-PPh3), 132.23, 131.85, (Cpara-Ph), 129.77 (Cmeta-
Ph), 128.97, 128.86, (d, Cortho-PPh3, 2JC–P12.26, 11.60 Hz), 127.85
(Cortho-Ph), 127.21, 126.63, (d, Cquaternary-PPh3, 1JC–P 66.90, 57.59 Hz),
66.36 and 53.44 (2CH2), 49.45 and 47.58 (2CH2). 31P{1H} NMR
(161.98 MHz, CH2Cl2): δ (ppm) = 21.03, 8.78 (d), 2JP-P = 24.29 Hz,
29.95 (d); 10.73 (d); 2JPt-P = 31.22 Hz, 21.16 (d); –2.60 (d); 2JPt-P =
38.53, Hz –144.51, (m, PF6–).
4.4. X-ray crystallography
A suitable single crystal was obtained by slow evaporation of
CHCl3:n-hexane (3:1) solution of the complex. Diffraction data were
collected on an Enraf-Nonius Kappa-CCD diffractometer with graph-
ite-monochromated Mo-Kα radiation (λ = 0.71073 Å) at 293(2) K.
The final unit cell parameters were based on all reflections. Data
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Unit cell dimensions a = 11.4855(6) Å
b = 14.8935(7) Å






ρ calcd. /mg mm–3 1.608
μ /mm–1 3.265
F(000) 1108
Crystal size /mm3 0.313 × 0.127 × 0.03
Theta range for data collection 2.56 to 26.00°
Index ranges –14 ≤ h ≤ 14
–18 ≤ k ≤ 16
–18 ≤ l ≤ 18
Reflections collected 25830
Independent reflections 9018 [R(int) = 0.0610]
Data/restraints/parameters 9018/0/496
Goodness-of-fit on F2 1.070
Final R indexes [I > 2σ (I)] R1 = 0.0420, wR2 = 0.1014
Largest diff. peak/hole /e Å–3 2.544/–1.759
collection was performed using the COLLECT program,[53] integra-
tion and scaling of the reflections were performed with the HKL
Denzo-Scalepack system of programs.[54] Absorption correction was
carried out using the Gaussian method.[55] The structure was solved
by direct methods and refined by full-matrix least-squares on F2 by
means of SHELX-97 package.[56] Hydrogen atoms were stereochemi-
cally positioned and refined with the riding model. Data collection
and experimental details are summarized in Table 3.
The molecular and packing diagrams were generated using
Ortep[57] and Mercury, respectively.[58] Puckering parameters were
calculated using Platon for Windows.[59] Exact cone (θ°) and exact
solid cone (Θ°) angles were computed using the Mathematica pack-
ages FindConeAngle[20] and FindSolidAngle,[22] respectively. The
solid angles and G-parameters were calculated with Solid-G soft-
ware.[23]
CCDC 1030349 (for 1) contains the supplementary crystallographic
data for this paper. These data can be obtained free of charge from
The Cambridge Crystallographic Data Centre.
4.5. Biological activity
4.5.1. Cell culture assay. The title complex was assayed against
human breast tumor cell line MDA-MB-231 (ATCC: HTB-26), DU-145,
human prostate cancer cells (ATCC: HTB-81) and against the L929
cell line (ATCC: CCL-1). The cells MDAMB-231 and L929 routinely
maintained in Dulbecco′s modified Eagle′s medium (DMEM) supple-
mented with 10 % fetal bovine serum (FBS); the DU-145 cells were
maintained in RPMI-1640 supplemented with10 % FBS, at 37 °C in
a humidified 5 % CO2 atmosphere. After reaching confluence, the
cells were detached by trypsinization and counted. For the cyto-
toxicity assay, 1.5 × 104 cells well–1 were seeded in 200 μL of com-
plete medium in 96-well assay microplates. The plates were incu-
bated at 37 °C in 5 % CO2 for 24 h to allow cell adhesion. The tested
compound was dissolved in sterile DMSO (stock solution with maxi-
mum concentration of 20 mmol L–1) and diluted to 20, 10, 5, 0.25,
0.62, 0.15, 0.039 mmol L–1.
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From diluted compound 1μL aliquots were added to 200 μL me-
dium giving a final concentration of approximately 0.5 % of DMSO
and a final concentration of the complex diluted of about 100 times.
Cells were exposed to the compound during a 48 h-period. Cell
respiration, as an indicator of cell viability, was determined by the
mitochondrial-dependent reduction of MTT [3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide] to formazan.[60] MTT solu-
tion (0.5 mg/mL) was added to cell culture and incubated for 3 h,
after which 100 μL of 2-propanol was added to dissolve the precipi-
tated formazan crystals. The conversion of MTT to formazan by met-
abolically viable cells was monitored in an automated microplate
reader at 540 nm. The percent cell viability was calculated by divid-
ing the average absorbance of the cells treated with the test com-
pound by that of the control. The % cell viability was plotted
against drug concentration (logarithmic scale) to determine the IC50
(drug concentration at which 50 % of the cells are viable in relation
to the control), with the error estimated from the average of 3 trials.
4.5.2. Anti-mycobacterial activity. The anti-mycobacterium
tuberculosis activity of the complex was determined by the REMA
(resazurin microtiter assay) method.[61] Stock solutions of the tested
compounds were prepared in DMSO and diluted in Middlebrook
7H9 broth (Difco) supplemented with oleic acid, albumin, dextrose
and catalase (OADC), performed by Precision XS (Biotek®) to obtain
the final drug concentration range of 0.09–25 μg mL–1. Isoniazid
was dissolved in distilled water and rifampicin in DMSO, and both
were used as standard drugs. A suspension of MTB H37Rv ATCC
27294 was cultured in Middlebrook 7H9 broth supplemented with
OADC and 0.05 % Tween 80.
The cultures were frozen at –80 °C in aliquots. After two days the
CFU per mL (colony formation unit per mL) of an aliquot was deter-
mined. The concentrations were adjusted by 5 × 105 CFU per mL
and 100 μL of the inoculum were added to each well of a 96-well
microplate together with 100 μL of the compounds. Samples were
set up in triplicate. The plates were incubated for 7 days at 37 °C.
Resazurin (solubilized in water) was added (30 μL of 0.01 %). The
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fluorescence of the wells was read after 24 h with a Cytation 3
(Biotek®). The MIC (minimum inhibitory concentration) was defined
as the lowest concentration resulting in 90 % inhibition of MTB
growth.
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